Home
Pain Therapeutics
19 May - 20 May 2014
Pain Therapeutics

SAE Media Group are proud to present their 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014. 

This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.

The agenda will give delegates an in-depth analysis on the strategies from bench to bedside  to enhance drug development.

New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.

The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.

 New sessions for 2014 will include:


• Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction

 

FEATURED SPEAKERS

Birgit  Priest

Birgit Priest

Senior Scientist , Eli Lilly
Kathleen Kelly

Kathleen Kelly

Medical Leader, Janssen Pharmaceutical Research and Development LLC
Misha  Backonja

Misha Backonja

Medical Director, Neuroscience , PRA International
Tom McCarthy

Tom McCarthy

Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
Zara Sands

Zara Sands

Computational Medicinial Chemist, UCB

Alexander Oksche

Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG
Alexander Oksche

Birgit Priest

Senior Scientist , Eli Lilly
Birgit  Priest

Chas Bountra

Chief Scientist, Structural Genomics Consortium, University of Oxford
Chas Bountra

Fiona Boissonade

Head of Neuroscience Research Group, The University Of Sheffield
Fiona Boissonade

Howard Gutstein

Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center
Howard Gutstein

Jarkko Kalliomaki

Senior Consultant Physician , Stockholm Brain Institute
Jarkko Kalliomaki

Jordi Serra

CSO , Neuroscience Technologies Ltd
Jordi Serra

Kathleen Kelly

Medical Leader, Janssen Pharmaceutical Research and Development LLC
Kathleen Kelly

Misha Backonja

Medical Director, Neuroscience , PRA International
Misha  Backonja

Odd-Geir Berge

Independent Consultant, OGBConsulting
Odd-Geir  Berge

Philip Kym

Associate Director II, Pain Discovery Research, Abbott Laboratories
Philip Kym

Praveen Anand

Professor, Clinical Neurology,, Imperial College London
Praveen Anand

Stephen Wright

Director, R&D, G W Pharmaceuticals
Stephen Wright

Steve Harrison

Vice President, Research Biology, Nektar Therapeutics
Steve  Harrison

Tom McCarthy

Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
Tom McCarthy

Zara Sands

Computational Medicinial Chemist, UCB
Zara Sands

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Kathleen Kelly

Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research and Development LLC

clock

9:10

Overview of Fulranumab Clinical Development

Kathleen Kelly

Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research and Development LLC

  • Nerve Growth factor (NGF) is elevated in tissues in response to injury and inflammation
  •  Antibody inhibitors of NGF have shown efficacy in treating pain
  • Fulranumab is a fully human monoclonal antibody inhibitor of NGF in development
  • Phase 2 efficacy and safety data for fulranumab will be presented
  • clock

    9:50

    Strategies for Designing Novel Therapeutic Modulators

    Zara Sands

    Zara Sands, Computational Medicinial Chemist, UCB

  • Importance of establishing expectations and aligning resources accordingly
  • Examples of effective applications of computational approaches for driving drug design cycles
  • Potenital pit falls and future prospects
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Mechanistic studies supporting the angiotensin II type 2 receptor antagonist MOA in chronic pain through to presentation of Phase 2 efficacy and safety data

    Tom McCarthy

    Tom McCarthy, Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals

  • Efficacy data from a 183 patient Phase 2 clinical trial of EMA401 in patients with post herpetic neuralgia
  • Safety data from the above study
  • Update on ongoing clinical trials of EMA401
  • clock

    12:20

    Round Table Discussion: Should animal models only be used for PK/PD testing for exposure of the compound?

    clock

    12:50

    Networking Lunch

    clock

    13:50

    How do we produce a step change in the discovery of new analgesics?

    Chas Bountra

    Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford

  • Epigenetic proteins are fundamental mediators of chronic pain pathology
  • In early discovery, more open partnerships between academia and industry are critical
  • In vitro clinical assays are likely more perspective of activity in patients
  • clock

    14:30

    Highlights from AbbVie Pain Research: TRPV1, TrkA, Cav2.2, and Nav1.7

    Philip Kym

    Philip Kym, Associate Director II, Pain Discovery Research, Abbott Laboratories

  • The discovery of modality specific TRPV1 antagonists that demonstrate reduced liabilities with respect to core body temperature increase and the loss of sensation of noxious heat.
  •  The discovery of Cav2.2 and Nav1.7 clinical candidates for the treatment of chronic pain.
  • The discovery of TrkA inhibitors for the treatment of chronic pain.
  •  

    clock

    15:10

    Afternoon Tea

     

     

    clock

    15:40

    The Translational Gap and Assessing Failures Case Study 1: Pre-Clinical Perspective

    Odd-Geir  Berge

    Odd-Geir Berge, Independent Consultant, OGBConsulting

  • Experimental models versus clinical trials
  • Translation from animal models to man
  • Failed pain mechanisms? 
  • clock

    16:20

    The Translational Gap and Assessing Failures Case Study 2:Clinical Perspective

    Jarkko Kalliomaki

    Jarkko Kalliomaki , Senior Consultant Physician , Stockholm Brain Institute

  • Translation from a clinical perspective
  • Human proof of concept
  • Failed mechanisms or failed studies? 
  • clock

    17:00

    Panel Discussion

  • Addressing issues in clinical trial design
  • Bridging the translational gap between animal and human model
  • Identifying key challenges in design when bench marking
  • Odd-Geir  Berge

    Odd-Geir Berge, Independent Consultant, OGBConsulting

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

    Jarkko Kalliomaki

    Jarkko Kalliomaki , Senior Consultant Physician , Stockholm Brain Institute

    Birgit  Priest

    Birgit Priest , Senior Scientist , Eli Lilly

    clock

    17:40

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Jordi Serra

    Jordi Serra, CSO , Neuroscience Technologies Ltd

    clock

    9:10

    Opioids and the Treatmnet of Chronic Pain

    Alexander Oksche

    Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG

  • How has the new form of Oxycontin made a difference- controlled release
  • Reviewing novel formulation strategies to reduce opioid abuse
  • Analysing the recent advances to opioids – moving forward
  • clock

    9:50

    Novel Opioid Therapuetics with Intrinsically Reduced Abuse Potential

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

  • NKTR-181, a slow brain entry opioid for Chronic Pain
  • Opioid therapeutics with novel pharmacoloyg for the treatment of actue pain
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Zero Tolerance for Chronic Pain

    Howard Gutstein

    Howard Gutstein, Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center

  • Growth factor signaling selectively mediates tolerance to morphine.
  • Growth factor inhibition eliminates or reverses morphine tolerance.
  • Newly discovered relationships between opioid tolerance and neuropathic pain suggests that this class of drugs could become important therapeutic targets for pain treatment
  • clock

    11:40

    Discussion Panel: Strategies for reduced abuse potential

  • Insights into the future of opioids
  • Assessing alternatives to opioid therapeutics
  • Evaluating how to move forward to minimise opioid misuse
  • Alexander Oksche

    Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

    Howard Gutstein

    Howard Gutstein, Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Translational Pain Medicine (TPM) - assessing pain mechanisms

    Misha  Backonja

    Misha Backonja, Medical Director, Neuroscience , PRA International

  • Current status of translational research in pain 
  • Missing link - bedside to bench and its relevance
  • Standards in utilizing the best tool - QST
  • Interpretation of results in TPM
  • clock

    14:00

    New Tools in the Translation from Bench to Clinic

    Birgit  Priest

    Birgit Priest , Senior Scientist , Eli Lilly

  • Failure of recent developmental compounds to demonstrate analgesic efficacy in the clinic
  • Possible explanations based on divergent pharmacology
  • New tools and approahces to better predict human pharmacology and efficacy
  • clock

    14:40

    Microneurography as a method for recording individual action potentials from nociceptors and its value in drug development in neuropathic pain.

    Jordi Serra

    Jordi Serra, CSO , Neuroscience Technologies Ltd

  • Analysing analgesic efficacy in preclinical animal modells
  • Reviewing proof-of-concept studies that allow critical testing of presumed mechanism of actions
  • Recording individual action potentials from single sensory fibers, including nociceptors to detect and quantify abnormal activity in human pain fibers
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    Cannabinoids in neuropathic pain: what have we learnt?

    Stephen Wright

    Stephen Wright, Director, R&D, G W Pharmaceuticals

  • Responses to cannabinoids across different neuropathic pain types
  • The importance of non-psychoactive cannabinoids
  • Cannabinoid modulation of neurotransmission vs inflammation
  • clock

    16:30

    Advances into new therapeutic strategies for chronic pain

    Fiona Boissonade

    Fiona Boissonade, Head of Neuroscience Research Group, The University Of Sheffield

  • Correlation between degree of pain and molecular targets in man
  • Translation from preclinical models
  • Interventions to prevent or reverse neuropathic pain
  • clock

    17:10

    Chairman's Closing Remarks and Close of Day Two


    Exec Director European Pharmacol Intelligence
    Mundipharma Research GmbH & Co. KG
    Senior Scientist
    Eli Lilly
    Chief Scientist, Structural Genomics Consortium
    University of Oxford
    Head of Neuroscience Research Group
    The University Of Sheffield
    Professor, Department of Anesthesiology and Biochemistry
    Anderson Cancer Center
    Senior Consultant Physician
    Stockholm Brain Institute
    CSO
    Neuroscience Technologies Ltd
    Medical Leader
    Janssen Pharmaceutical Research and Development LLC
    Medical Director, Neuroscience
    PRA International
    Independent Consultant
    OGBConsulting
    Associate Director II, Pain Discovery Research
    Abbott Laboratories
    Professor, Clinical Neurology,
    Imperial College London
    Director, R&D
    G W Pharmaceuticals
    Vice President, Research Biology
    Nektar Therapeutics
    Chief Executive Officer and Managing Director
    Spinifex Pharmaceuticals
    Computational Medicinial Chemist
    UCB

    Interview with OGBConsulting

    Download

    Interview with Philip Kym

    Download

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.